BioDelivery Sciences International (BioDelivery Sciences International) Debt-to-Equity : 0.31 (As of Dec. 2021)

View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Debt-to-Equity?

BioDelivery Sciences International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $4.6 Mil. BioDelivery Sciences International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $54.2 Mil. BioDelivery Sciences International's Total Stockholders Equity for the quarter that ended in Dec. 2021 was $187.8 Mil. BioDelivery Sciences International's debt to equity for the quarter that ended in Dec. 2021 was 0.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioDelivery Sciences International's Debt-to-Equity or its related term are showing as below:

BDSI' s Debt-to-Equity Range Over the Past 10 Years
Min: -23.62 Med: 0.17 Max: 5.37
Current: 0.31

During the past 13 years, the highest Debt-to-Equity Ratio of BioDelivery Sciences International was 5.37. The lowest was -23.62. And the median was 0.17.

BDSI's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28 vs BDSI: 0.31

BioDelivery Sciences International Debt-to-Equity Historical Data

The historical data trend for BioDelivery Sciences International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Debt-to-Equity Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

5.37

1.74

0.84

0.73

0.31

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Debt-to-Equity	Get a 7-Day Free Trial															0.73	0.72	0.69	0.48	0.31

Competitive Comparison of BioDelivery Sciences International's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioDelivery Sciences International's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Debt-to-Equity falls into.

BioDelivery Sciences International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioDelivery Sciences International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.615	+	54.177)	/	187.822
	=	0.31

BioDelivery Sciences International's Debt to Equity Ratio for the quarter that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.615	+	54.177)	/	187.822
	=	0.31

BioDelivery Sciences International (NAS:BDSI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioDelivery Sciences International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Executives

James Vollins	officer: See Remarks	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd	director	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho	officer: See Remarks	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey	director, officer: Chief Executive Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc	director	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha	officer: See Remarks	1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr	director	BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier	director, officer: Chief Executive Officer	C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith	officer: Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612